Clolar Confirmatory Study Should Be In Early-Relapse Patients, Cmte. Says
Executive Summary
Genzyme's confirmatory study for Clolar should be conducted in an early-relapse leukemia pediatric population, members of the Oncologic Drugs Advisory Committee Pediatric Subcommittee said Oct. 20
You may also be interested in...
Clolar Launching For Pediatric ALL; Genzyme, FDA Discussing Adult Studies
Genzyme will employ a sales force of less than 10 to launch Clolar for pediatric acute lymphoblastic leukemia in January
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials